659 related articles for article (PubMed ID: 28188133)
21. L-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia.
Jung KS; Cho SH; Kim SJ; Ko YH; Kang ES; Kim WS
J Hematol Oncol; 2016 Apr; 9():41. PubMed ID: 27091029
[TBL] [Abstract][Full Text] [Related]
22. Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resource-constrained setting.
Chan TSY; Hwang YY; Khong PL; Leung AYH; Chim CS; Tse EWC; Kwong YL
Hematol Oncol; 2020 Dec; 38(5):726-736. PubMed ID: 32786092
[TBL] [Abstract][Full Text] [Related]
23. Chemorefractory extranodal nasal-type natural-killer/T-cell lymphoma with great response to pembrolizumab in a young patient: a case report.
Adabifirouzjaei F; Khazai B; Azami G; Shoja-E-Razavi G
J Med Case Rep; 2021 Oct; 15(1):539. PubMed ID: 34702349
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis and management of extranodal NK/T cell lymphoma nasal type.
Tse E; Kwong YL
Expert Rev Hematol; 2016 Sep; 9(9):861-71. PubMed ID: 27347812
[TBL] [Abstract][Full Text] [Related]
25. Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation.
Prockop S; Doubrovina E; Suser S; Heller G; Barker J; Dahi P; Perales MA; Papadopoulos E; Sauter C; Castro-Malaspina H; Boulad F; Curran KJ; Giralt S; Gyurkocza B; Hsu KC; Jakubowski A; Hanash AM; Kernan NA; Kobos R; Koehne G; Landau H; Ponce D; Spitzer B; Young JW; Behr G; Dunphy M; Haque S; Teruya-Feldstein J; Arcila M; Moung C; Hsu S; Hasan A; O'Reilly RJ
J Clin Invest; 2020 Feb; 130(2):733-747. PubMed ID: 31689242
[TBL] [Abstract][Full Text] [Related]
26. Recent Advances in the Diagnosis and Treatment of Natural Killer Cell Malignancies.
Tse E; Kwong YL
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158865
[TBL] [Abstract][Full Text] [Related]
27. Review on natural killer/T-cell lymphoma.
He X; Gao Y; Li Z; Huang H
Hematol Oncol; 2023 Apr; 41(2):221-229. PubMed ID: 34731509
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in the diagnosis and treatment of natural killer/T-cell lymphomas.
Tse E; Au-Yeung R; Kwong YL
Expert Rev Hematol; 2019 Nov; 12(11):927-935. PubMed ID: 31487202
[No Abstract] [Full Text] [Related]
29. Combined immune checkpoint blockade and radiotherapy induces durable remission in relapsed natural killer/T-cell lymphoma: a case report and review of the literature.
McGehee E; Patel H; Pearson C; Clements K; Jaso JM; Chen W; Callan A; Desai N; Ramakrishnan Geethakumari P
J Med Case Rep; 2021 Apr; 15(1):221. PubMed ID: 33926575
[TBL] [Abstract][Full Text] [Related]
30. How I treat NK/T-cell lymphomas.
Tse E; Kwong YL
Blood; 2013 Jun; 121(25):4997-5005. PubMed ID: 23652805
[TBL] [Abstract][Full Text] [Related]
31. [Incidence and treatment of extranodal natural killer/T-cell lymphoma nasal type. Hungarian experiences].
Bakos A; Szomor Á; Schneider T; Miltényi Z; Marton I; Borbényi Z; Pammer J; Krenács L; Bagdi E; Piukovics K
Orv Hetil; 2017 Oct; 158(41):1635-1641. PubMed ID: 29025287
[TBL] [Abstract][Full Text] [Related]
32. Allogeneic hematopoietic stem cell transplant following chemotherapy containing l-asparaginase as a promising treatment for patients with relapsed or refractory extranodal natural killer/T cell lymphoma, nasal type.
Yokoyama H; Yamamoto J; Tohmiya Y; Yamada MF; Ohguchi H; Ohnishi Y; Okitsu Y; Fukuhara N; Ohba-Ohtsuka R; Kohata K; Ishizawa K; Kameoka J; Harigae H
Leuk Lymphoma; 2010 Aug; 51(8):1509-12. PubMed ID: 20496989
[TBL] [Abstract][Full Text] [Related]
33. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma.
Li X; Cheng Y; Zhang M; Yan J; Li L; Fu X; Zhang X; Chang Y; Sun Z; Yu H; Zhang L; Wang X; Wu J; Li Z; Nan F; Tian L; Li W; Young KH
J Hematol Oncol; 2018 Jan; 11(1):15. PubMed ID: 29386072
[TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma.
Pfeffermann LM; Pfirrmann V; Huenecke S; Bremm M; Bonig H; Kvasnicka HM; Klingebiel T; Bader P; Rettinger E
Cytotherapy; 2018 Jun; 20(6):839-850. PubMed ID: 29754771
[TBL] [Abstract][Full Text] [Related]
35. Optimization of immune checkpoint inhibitor treatment planning for relapsed or refractory extranodal NK/T cell lymphoma.
Yoon SE; Cho H; Berning P; Cho J; Kim HY; Yoon DH; Schmit N; Kim SJ; Kim WS
Ann Hematol; 2024 May; ():. PubMed ID: 38730207
[TBL] [Abstract][Full Text] [Related]
36. Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution.
Huang Y; Rao H; Yan S; Wang F; Wu Q; Feng Y; Zhang Y
Ann Hematol; 2017 Aug; 96(8):1331-1342. PubMed ID: 28550598
[TBL] [Abstract][Full Text] [Related]
37. Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma.
Cho J; Kim SJ; Park S; Yoo KH; Ki CS; Ko Y; Kim WS
Ann Hematol; 2018 Aug; 97(8):1427-1436. PubMed ID: 29627879
[TBL] [Abstract][Full Text] [Related]
38. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.
Haverkos BM; Abbott D; Hamadani M; Armand P; Flowers ME; Merryman R; Kamdar M; Kanate AS; Saad A; Mehta A; Ganguly S; Fenske TS; Hari P; Lowsky R; Andritsos L; Jagasia M; Bashey A; Brown S; Bachanova V; Stephens D; Mineishi S; Nakamura R; Chen YB; Blazar BR; Gutman J; Devine SM
Blood; 2017 Jul; 130(2):221-228. PubMed ID: 28468799
[TBL] [Abstract][Full Text] [Related]
39. EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation.
McLaughlin LP; Rouce R; Gottschalk S; Torrano V; Carrum G; Wu MF; Hoq F; Grilley B; Marcogliese AM; Hanley PJ; Gee AP; Brenner MK; Rooney CM; Heslop HE; Bollard CM
Blood; 2018 Nov; 132(22):2351-2361. PubMed ID: 30262660
[TBL] [Abstract][Full Text] [Related]
40. Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management.
Tse E; Fox CP; Glover A; Yoon SE; Kim WS; Kwong YL
Semin Hematol; 2022 Oct; 59(4):198-209. PubMed ID: 36805888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
